BioCentury
ARTICLE | Clinical News

IDegLira regulatory update

August 19, 2013 7:00 AM UTC

Novo Nordisk disclosed in its 1H13 earnings that it submitted a regulatory application in Switzerland for IDegLira to treat Type II diabetes. IDegLira, which is under review in the EU, is a fixed-dose combination of Novo's Victoza liraglutide and the company's Tresiba insulin degludec. ...